Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer
Authors:
Open Access
- 9 March 2022
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 11 (1) , 2046931
Abstract
Recently, the inhibitory CD94/NKG2A receptor has joined the group of immune checkpoints (ICs) and its expression has been documented in NK cells and CD8+ T lymphocytes in several cancers and some infectious diseases. In colorectal cancer (CRC), we previously reported that NKG2A+ tumor-infiltrating lymphocytes (TILs) are predominantly CD8+ αβ T cells and that CD94 overexpression and/or its ligand HLA-E were associated with a poor prognosis. This study aimed to thoroughly characterize the NKG2A+ CD8+ TIL subpopulation and document the impact of NKG2A on anti-tumor responses in CRC. Our findings highlight new features of this subpopulation: (i) enrichment in colorectal tumors compared to paired normal colonic mucosa, (ii) their character as tissue-resident T cells and their majority terminal exhaustion status, (iii) co-expression of other ICs delineating two subgroups differing mainly in the level of NKG2A expression and the presence of PD-1, (iv) high functional avidity despite reduced proliferative capacity and finally (v) inhibition of anti-tumor reactivity that is overcome by blocking NKG2A. From a clinical point of view, these results open a promising alternative for immunotherapies based on NKG2A blockade in CRC, which could be performed alone or in combination with other IC inhibitors, adoptive cell transfer or therapeutic vaccination. Graphical AbstractKeywords
Funding Information
- by the Ligue contre le cancer Grand Ouest (Comités du Finistère, de Loire-Atlantique, Côtes d’Armor, Morbihan et Loir-et-Cher), DHU Oncogreffe, CHU Nantes (RC14-0416-1)
- Cancéropôle Grand Ouest (RC16-0212-1)
- Ligue Contre le Cancer
This publication has 52 references indexed in Scilit:
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory CheckpointsCancer Discovery, 2015
- Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patientsCellular Immunology, 2015
- Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV‐induced usual vulvar intraepithelial neoplasia and implications for immunotherapyInternational Journal of Cancer, 2014
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic SignaturesImmunity, 2013
- HLA‐E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progressionInternational Journal of Cancer, 2011
- HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytesProceedings of the National Academy of Sciences, 2011
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- GATA-3 Expression Is Controlled by TCR Signals and Regulates CD4/CD8 DifferentiationImmunity, 2003
- Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCRGastroenterology, 2002
- The CD94 and NKG2‐A C‐type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I moleculesEuropean Journal of Immunology, 1997